<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003206</url>
  </required_header>
  <id_info>
    <org_study_id>Multimodal MRI DBS-PD</org_study_id>
    <nct_id>NCT05003206</nct_id>
  </id_info>
  <brief_title>Predictive Value of Multimodal MRI in Parkinson's Disease</brief_title>
  <official_title>Multimodal Magnetic Resonance Imaging Studying the Mechanism and Predicting the Outcome After Deep Brain Stimulation in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep brain stimulation (DBS) is recognized as the most safe and effective neurosurgical&#xD;
      method for the treatment of advanced Parkinson's disease. However, the mechanism of relieving&#xD;
      motor and non-motor symptoms of Parkinson's disease has not been fully clarified, and the&#xD;
      prognosis is significantly different. This study is based on multimodal MRI technique to&#xD;
      clarify the mechanism of DBS in relieving motor and non-motor symptoms of Parkinson's&#xD;
      disease, and to explore imaging indicators that can predict prognosis, so as to guide the&#xD;
      individual and accurate treatment of Parkinson's disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Preoperative and postoperative multimodal MRI scanning 1) equipment: 3TGE 750 MRI 2)&#xD;
           sequence: resting state fMRI, DTI, 3DTI, ESWAN, ASL 3) scan status: drug shutdown period&#xD;
           ( discontinuation of drugs for Parkinson's disease for at least 12 hours), for patients&#xD;
           who can not adhere to MRI scanning after drug withdrawal. Record the dosage of drugs&#xD;
           before scanning&#xD;
&#xD;
        2. Evaluation of motor and non-motor symptoms: pre-operation and 1-year post-operation 1)&#xD;
           motor symptoms: pre-operation medication opening and closing period. Postoperative&#xD;
           medication off/stimulation off&#xD;
           (Med-OFF/DBS-OFF);Med-ON/DBS-OFF;Med-OFF/DBS-ON;Med-ON/DBS-ON&#xD;
&#xD;
             1. overall evaluation of motor function: MDS-UPRDS, H&amp;Y stage&#xD;
&#xD;
             2. balance: Berg balance scale&#xD;
&#xD;
             3. dyskinesia: abnormal involuntary movement scale(AIMS)&#xD;
&#xD;
             4. end-of-dose phenomenon: WOQ19 end-of-dose phenomenon questionnaire&#xD;
&#xD;
             5. daily activity ability: SCHWAB&amp;ENGLAND daily activity scale 2) non-motor symptoms:&#xD;
                preoperative drug shutdown period. Postoperative drug shutdown / DBS opening&#xD;
&#xD;
             1. Cognitive function: Mini Mental State Examination scale (MMSE), Montreal Cognitive&#xD;
                Assessment scale (MoCA)&#xD;
&#xD;
             2. emotion: Hamilton Depression scale (HAMD), Hamilton anxiety scale (HAMA)&#xD;
&#xD;
             3. Sleep: PD Sleep scale (PDSS), Appleworth sleepiness scale (ESS), REM Sleep&#xD;
                Behavioral Disorder questionnaire-Hong Kong (RBDQ-HK)&#xD;
&#xD;
             4. pain: King Parkinson's disease pain scale (KPPS)&#xD;
&#xD;
             5. fatigue: fatigue severity scale (FSS)&#xD;
&#xD;
             6. autonomic nervous function assessment: autonomic nervous scale (SCOPA-AUT) h)&#xD;
                quality of life: 39 items Parkinson's disease quality of life questionnaire&#xD;
                (PDQ-39) 3.other records: changes in type, dose and mode of use of drugs. Daily&#xD;
                equivalent dose of levodopa (tomlinson2010 conversion)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical characteristics of patients</measure>
    <time_frame>1 to 2 years</time_frame>
    <description>Age at onset; age at surgery; disease duration; level of education; comorbidities (e.g. hypertension and diabetes mellitus); parkinsonism subtype; period of motor fluctuations; time from motor fluctuations to surgery; cigarette smoking</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of improvement in motor aspects (after 12 months of stimulation)</measure>
    <time_frame>1 to 3 years</time_frame>
    <description>(UPDRS III 12 months - UPDRS III baseline)/UPDRS III baseline where UPDRS III 12 months means the score of this test in &quot;medication off , stimulation on&quot; condition at 12 months after implant, while UPDRS III baseline means the score of this test in &quot;medication off &quot; condition.The clinical outcome, or degree of symptom benefit, was defined as a â‰¥50% improvement on a disease severity rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>other records:</measure>
    <time_frame>1 to 3 years</time_frame>
    <description>Changes in type, dose and mode of use of drugs. Daily equivalent dose of levodopa (tomlinson2010 conversion)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Deep Brain Stimulation</condition>
  <arm_group>
    <arm_group_label>PD,DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with idiopathic PD before and after DBS surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functional magnetic resonance imaging</intervention_name>
    <description>Preoperative and postoperative functional magnetic resonance imaging (fMRI) scanning. fMRI is a new neuroimaging method. Its principle is to use magnetic resonance imaging to measure the changes of hemodynamics caused by neuronal activity.</description>
    <arm_group_label>PD,DBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation</intervention_name>
    <description>For PD patients treated with DBS, the neurologist will turn off the stimulator before MRI scan</description>
    <arm_group_label>PD,DBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with Parkinson's disease&#xD;
&#xD;
          -  age&lt; 70 years&#xD;
&#xD;
          -  Underwent bilateral STN-DBS or not&#xD;
&#xD;
          -  Having complete medical history and clinical follow up&#xD;
&#xD;
          -  All MRI examination performed according to study protocol&#xD;
&#xD;
          -  Imaging data can be processed&#xD;
&#xD;
          -  Signed informed consent obtained from the patient or patient's legally authorized&#xD;
             representative;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parkinson-plus syndrome or secondary parkinsonism&#xD;
&#xD;
          -  Patients with severe mental disorders such as psychosis, liver and kidney dysfunction,&#xD;
             poor blood pressure or blood glucose control, severe depression and substance abuse,&#xD;
             low IQ, and acute phase of severe stroke with definite limb dysfunction should also be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Lou</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yina Lan</last_name>
    <phone>+86-17326826301</phone>
    <email>lanyn1220@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-na Lan</last_name>
      <phone>+86-17326826301</phone>
      <email>lanyn1220@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xin Lou</investigator_full_name>
    <investigator_title>Deputy Director of Department of Radiology</investigator_title>
  </responsible_party>
  <keyword>Subthalamic nucleus deep brain stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

